Oruka Therapeutics Announces $180 Million Private Placement [Yahoo! Finance]
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: Yahoo! Finance
the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthcare Fund, Blackstone Multi-Asset Investing, Commodore Capital, Cormorant Asset Management, Deep Track Capital, Fairmount, Great Point Partners, LLC, Palo Alto Investors, LP, Perceptive Advisors, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners, Woodline Partners LP and a leading life sciences investment firm, among others. Pursuant to the terms of the securities pu
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ORKA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA) [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $56.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $45.00 price target on the stock.MarketBeat
- Oruka Therapeutics GAAP EPS of -$0.55 beats by $0.01 [Seeking Alpha]Seeking Alpha
ORKA
Earnings
- 11/12/25 - Beat
ORKA
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- 11/5/25 - Form 424B5
- ORKA's page on the SEC website